Clinical trials: Physiological Effects of Drugs
Suicide, Depressive Disorder, Treatment-Resistant
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, but it can take a long time for them to be effective.
- Conditions
- Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action
- Trial name
- NCT06511908
- Testing
- (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Mental Health (NIMH)
Behavioral Symptoms, Suicide
Natural History of Depression, Bipolar Disorder and Suicide Risk
Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments.
- Conditions
- Behavioral Symptoms, Suicide, Self-Injurious Behavior, Sensory System Agents
- Trial name
- NCT06462196
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Institute of Mental Health (NIMH)
Asperger's Disorder, Asperger Disorder
QAIAx (AIhealth4U) - AI Smart Health Cities: Microcity Enclave Program (Quantum AI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360)
BRIEF SUMMARY A. "What is the purpose of this study?" BACKGROUND. The QAIAx clinical trial (Quantum AI/AGI Public Health Agency), known operationally as the "AI City Hall Project," represents a landmark intergovernmental research…
- Conditions
- Asperger's Disorder, Asperger Disorder, Autism Disorder, Autism
- Trial name
- QAIAx (NCT07661823)
- Testing
- AI City Hall Project (AIhealth4u - Public Health Central), AI City Hall Project (QAIAx Microcity A - AI Public Health Central)
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Veterans Recovery Network Inc.
Neuromuscular Agents, Peripheral Nervous System Agents
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence.
- Conditions
- Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
- Trial name
- PLATINUM US (NCT07122193)
- Testing
- NT 201
- Where
- 28 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Merz North America, Inc.
Neuromuscular Agents, Peripheral Nervous System Agents
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)
The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence.
- Conditions
- Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
- Trial name
- PLATINUM EU (NCT07210463)
- Testing
- NT 201
- Where
- 26 sites in France, Germany and 2 more
- Volunteers
- 300 people
- Sponsor
- Merz Aesthetics GmbH
Prostatic Neoplasms, Neoplasm Metastasis
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
- Conditions
- Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
- Trial name
- CYCLONE 3 (NCT05288166)
- Testing
- Abemaciclib, Abiraterone, Prednisone or Prednisolone
- Where
- 266 sites in United States, Argentina and 22 more
- Volunteers
- 925 people
- Sponsor
- Eli Lilly and Company
Coronavirus, Coronavirus Infection
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate…
- Conditions
- Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia
- Trial name
- CYNKCOVID (NCT04365101)
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Celularity Incorporated
Physiological Effects of Drugs, Anesthetics
Effectiveness of the Comfort-In Needle Free Injection System During Palatal Infiltrative Anesthesia
The goal of this randomized clinical trial is to compare two different injection methods in children. The main question it aims to answer is: Is the needle-free injection method more painless than the traditional dental method?…
- Trial name
- NCT06606587
- Testing
- Comfort-in Jet Injection Method, Traditional Dental Injection
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Necmettin Erbakan University
Treatment Resistant Depression, Major Depressive Disorder
Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression
The purpose of this study is to assess the effects of simultaneous administration of oral aspirin and oral ketamine as a therapeutic for those with Treatment Resistant Depression.
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine
- Trial name
- NCT05615948
- Testing
- VTS-K
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Theresa Jacob, PhD, MPH
Coronary Disease, Heart Diseases
Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)
This international, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) compared to dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients…
- Conditions
- Coronary Disease, Heart Diseases, Cardiovascular Diseases, Myocardial Ischemia
- Trial name
- PIV-EPIC (NCT06535568)
- Testing
- Drug-coated balloon, Single antiplatelet therapy (SAPT), Dual antiplatelet therapy (DAPT)
- Where
- Italy
- Volunteers
- 576 people
- Sponsor
- Fondazione Ricerca e Innovazione Cardiovascolare ETS
Liver Cirrhosis, Fibrosis
Growth Hormone in Decompensated Liver Cirrhosis
Globally, cirrhosis and liver cancer carries a huge burden and accounts for about 3.5% (2 million) of all deaths every year. Once decompensated, i.e.
- Conditions
- Liver Cirrhosis, Fibrosis, End Stage Liver Disease, Digestive System Disease
- Trial name
- NCT05253287
- Testing
- Growth Hormone
- Where
- India
- Volunteers
- 96 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Delirium, Cognitive Dysfunction
Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients
Anesthesia is a drug induced, reversible, comatose state that facilitates surgery and it is widely assumed that cognition returns to baseline after anesthetics have been eliminated.
- Conditions
- Delirium, Cognitive Dysfunction, Cognition Disorder, Neurocognitive Disorders
- Trial name
- CODEX (NCT04289142)
- Testing
- Dexmedetomidine Hydrochloride Group
- Where
- 8 sites in Canada
- Volunteers
- 2,400 people
- Sponsor
- Sunnybrook Health Sciences Centre
Stroke, Acute Stroke
The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Dimephosphon® in acute ischemic stroke
- Conditions
- Stroke, Acute Stroke, Ischemic Stroke, Cerebrovascular Disorders
- Trial name
- NCT07167550
- Testing
- Dimephosphon®
- Where
- 6 sites in Russia
- Volunteers
- 184 people
- Sponsor
- Tatchempharmpreparaty, JSC
Vaccines, Antiviral Agents
Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products
Background: Vaccines and antiviral therapies help prevent and treat diseases. Researchers need a group of healthy volunteers for clinical trials. Clinical trials are studies that test these vaccines and therapies in people.
- Conditions
- Vaccines, Antiviral Agents, Immunologic Factors, Physiological Effects of Drugs
- Trial name
- NCT02242968
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Virus Diseases, Hemorrhagic Fever, Ebola
Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study
This is a Phase 2, open-label, study evaluating the safety and immunogenicity of the 2-dose vaccination regimen, Ad26.ZEBOV, MVA-BN-Filo, in adults and children originally enrolled in the control arm of the EBOVAC-Salone study
- Conditions
- Virus Diseases, Hemorrhagic Fever, Ebola, Infections, Hemorrhagic Fevers, Viral
- Trial name
- NCT05284097
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- Sierra Leone
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes
Antidiabetic Drugs for Steatotic Liver Disease
To investigate the synergic therapeutic effect of thiazolidinediones and SGLT2 inhibitor on metabolic dysfunction-associated steatotic liver disease, the effect of empagliflozin 10mg, pioglitazone 15mg monotherapy and combination…
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes, Digestive System Disease, Liver Diseases
- Trial name
- NCT03646292
- Testing
- Pioglitazone, Empagliflozin, Combination of pioglitazone and empagliflozin
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Yonsei University
Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders
Sex, Psychopharmacology, and Diabetes
The term sexual (SD) dysfunction covers conditions that prevent people from having a satisfactory sex life. SD is a frequent and sometimes debilitating complication of mental illness and a known adverse reaction to…
- Conditions
- Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Diabetes Mellitus, PreDiabetes
- Trial name
- SECRET (NCT05951660)
- Testing
- Educational intervention
- Where
- Denmark
- Volunteers
- 256 people
- Sponsor
- Zealand University Hospital
Alcohol Drinking, Drinking Behavior
Behavior Brain Responses
To compare responses to acute oral doses of ethanol in healthy young adults who experience mainly stimulant subjective effects from the drug or mainly sedative effects.
- Conditions
- Alcohol Drinking, Drinking Behavior, Physiological Effects of Drugs, Central Nervous System Depression
- Trial name
- BBR (NCT03964350)
- Testing
- Ethanol
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Leukemia, Leukemia, Myeloid
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type
- Trial name
- CYNK001AML01 (NCT04310592)
- Testing
- CYNK-001
- Where
- 10 sites in United States
- Volunteers
- 27 people
- Sponsor
- Celularity Incorporated
Food IgE-mediated Allergy, Immunotherapy
Omalizumab to Accelerate a Symptom-driven Multi-food OIT
This study will determine the dose-related efficacy of a 20-week treatment of omalizumab started 8 weeks before the onset of a symptom-driven multi-food oral immunotherapy (OIT) protocol at decreasing time to OIT maintenance…
- Conditions
- Food IgE-mediated Allergy, Immunotherapy, Omalizumab, Physiological Effects of Drugs
- Trial name
- BOOM (NCT04045301)
- Testing
- Omalizumab 16mg/kg, Omalizumab 8mg/kg, Multi-food oral immunotherapy (OIT)
- Where
- 3 sites in Canada
- Volunteers
- 90 people
- Sponsor
- Philippe Bégin